Search Results
Placement Agent on Skye Bioscience's $50MM Private Placement Financing
Oppenheimer &. Co. Inc. acted as Placement Agent on Skye Bioscience’s $50MM Private Placement Financing
Placement Agent on Skye Bioscience's $40MM Private Placement
Oppenheimer &. Co. Inc. acted as Placement Agent on Skye Bioscience’s $40MM Private Placement
Placement Agent on Q32 Bio's Private Placement Financing
Oppenheimer &. Co. Inc. acted as Placement Agent on Q32 Bio’s $42MM Private Placement Financing
Placement Agent on Protara Therapeutics' $45MM Private Placement Financing
Oppenheimer &. Co. Inc. acted as Placement Agent on Protara Therapeutics’ $45MM Private Placement Financing
Placement Agent on Olema Pharmaceuticals' Private Placement Financing
Oppenheimer & Co. Inc. acted as Placement Agent on Olema Pharmaceuticals’ $250MM Private Placement Financing
Oppenheimer Healthcare Q1 Snapshot
Oppenheimer's 2023 Year-in-Review and 2024 Outlook for Private Placement Activity and M&A and Strategic Collaborations are now available upon request.
M&A Adviser to Alchemist Learning & Development on Securing Significant Investment from Horizon Capital
Oppenheimer’s European Human Capital Management Investment Banking Team is pleased to announce it has advised Rockpool Investments' portfolio company Alchemist Learning & Development on securing significant investment from Horizon Capital
Lead-Left Bookrunner on Black Sky Technology Inc's Follow-On Offering
Oppenheimer & Co. Inc. acted as Lead-Left Bookrunner on the upsized $46,000,000 Confidentially Marketed Follow-On Offering for BlackSky Technology Inc.(NASDAQ: BKSY)
Lead Placement Agent on Perspective Therapeutics' $87.4MM Private Placement
Oppenheimer & Co. Inc. acted as Lead Placement Agent on Perspective Therapeutics' $87.4MM Private Placement
Lead Manager on Aquestive Therapeutics' Confidentially Marketed Public Offering
Oppenheimer &. Co. Inc. acted as Lead Manager on Aquestive Therapeutics' Confidentially Marketed Public Offering